However, because NGS does not screen solely for fusion proteins (such as BCR/ABL1) and instead looks at the sum of all randomized VDJ IGH regions, it may be reasonable to extrapolate results comparing peripheral blood and bone marrow MRD evaluation in Ph- ALL. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.